Assessment of C-Reactive Protein for Diagnosis and Monitoring in Pediatric Pulmonary TB
Overview
In a cohort of 292 Kenyan children, C-reactive protein (CRP) demonstrated limited sensitivity for diagnosing pulmonary tuberculosis (TB) but showed significant decreases during treatment among children with elevated baseline CRP. CRP levels decreased notably in children with confirmed or unconfirmed TB, particularly those with baseline CRP ≥5 mg/L.
Background
Pediatric tuberculosis diagnosis is challenging due to frequent extrapulmonary or disseminated disease and limitations of respiratory sampling. Non-sputum-based biomarkers like CRP, an acute-phase protein elevated in infections, may aid diagnosis and treatment monitoring. While CRP is endorsed for TB screening in HIV-positive adults, its utility in HIV-negative children remains underexplored. This study evaluated CRP as a diagnostic and treatment response biomarker in symptomatic Kenyan children.
Data Highlights
CRP Threshold (mg/L)
Sensitivity for Confirmed TB (%)
Sensitivity for Unconfirmed TB (%)
Specificity for Unlikely TB (%)
5
50.0 (26.0–74.0)
35.5 (29.0–42.4)
71.3 (60.4–80.6)
10
44.4 (21.5–69.2)
28.4 (22.2–35.4)
Not specified
Key Findings
Baseline median CRP levels did not significantly differ between children with confirmed, unconfirmed, or unlikely TB.
At a 5 mg/L cutoff, CRP sensitivity was 50% for confirmed TB and 35.5% for unconfirmed TB, with 71.3% specificity for unlikely TB.
CRP sensitivity decreased at a 10 mg/L cutoff, indicating lower diagnostic sensitivity at higher thresholds.
CRP levels significantly decreased during TB treatment in children with confirmed (P = .02) and unconfirmed TB (P < .001), especially those with baseline CRP ≥5 mg/L.
Approximately 40% of children had elevated baseline CRP (≥5 mg/L), who showed the most pronounced treatment-related CRP decline.
Clinical Implications
CRP alone has limited sensitivity for diagnosing pediatric pulmonary TB and should not replace existing diagnostic methods. However, serial CRP measurements may be useful to monitor treatment response, particularly in children with elevated baseline CRP. Incorporating CRP monitoring could aid clinicians in assessing treatment efficacy in resource-limited settings.
Conclusion
CRP is not sufficiently sensitive as a standalone diagnostic biomarker for pediatric pulmonary TB but shows promise as a tool for monitoring treatment response in children with elevated baseline CRP levels. Further research is warranted to optimize its clinical utility.
References
Kenya Medical Research Institute et al. 2023 -- Assessment of C-Reactive Protein as a Biomarker for Diagnosing and Monitoring Treatment in Pediatric Pulmonary Tuberculosis
Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.
